Knobbe Martens
Gregory B. Phillips is a partner at Knobbe Martens Olson & Bear LLP, where since May 2006, expertise has been applied in counseling clients on domestic and international trademark, copyright, and trade dress issues, along with litigation and opposition/cancellation matters. Prior to this role, Gregory served as a paralegal at Latham & Watkins from May 1999 to May 2006, managing trademark portfolios for Fortune 500 and mid-sized companies and conducting intellectual property due diligence for corporate transactions. Gregory holds a JD, cum laude, from Loyola Law School, Los Angeles (2003-2007), and a Bachelor’s degree in History and Business from UCLA (1986-1991).
This person is not in any teams
This person is not in any offices
Knobbe Martens
2 followers
Our firm boasts IP law’s largest and most experienced biotechnology group, with more than 60 attorneys and scientists representing clients in all stages of their business and technology development. Our clients are innovators in a variety of disciplines including PCR, molecular tools and probes, immunology (antibodies and other binding proteins), cell varieties and uses (including stem cells) and biological polymers, to name but a few. Our expertise across the entire biotech landscape gives us great insight into specific technologies, systems and markets. More importantly, our holistic understanding of the interrelated technologies and systems typically involved in a single invention allows us to provide coordinated guidance and counsel from inception though introduction. Working in collaboration with more than 300 IP firms worldwide, we effect patent, trademark, copyright, and other filings, and direct oppositions, cancellations, and litigation matters in over 120 countries. We have considerable experience in negotiating and drafting traditional licensing agreements as well as agreements for strategic alliances, partnerships and joint ventures. We also maintain a talented litigation department adept in all aspects of biotechnology IP law, including the Biosimilars legislation. Our extensive Hatch-Waxman litigation experience combined with our understanding of the biotechnology industry uniquely positions Knobbe Martens to help clients develop and implement litigation strategies designed to maximize their place in the Biosimilars market place. In addition, we have considerable experience litigating before the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission. Our attorneys have experience in all areas of Biotechnology, including: Aesthetic & Cosmetic Biotechnology Antibodies & Immunology Biofuels Biological Manufacturing Of Chemicals Biologics Diagnostic Tools Genomics Industrial Enzymes Peptides Personalized Medicine Research Tools & Reagents Stem Cells & Regenerative Medicine Synthetic Biology & Nanotechnology Therapeutics Tissue Engineering Transgenic Animals Vaccines